Mesoblast Limited 2025 Annual Report and Corporate Governance Update

Mesoblast Limited filed its 2025 Annual Report and related documents with the Australian Securities Exchange on October 28, 2025. The filing includes the Annual Report to Shareholders, Notice of Annual General Meeting, and the Appendix 4G and Corporate Governance Statement. The Annual Report highlights significant milestones, including the FDA approval of Ryoncil® for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD), marking a pivotal transition from development to commercialization. The report also outlines strategic priorities such as the successful commercial launch of Ryoncil®, operational excellence, manufacturing efficiencies, and filings for approval of Rexlemestrocel-L for cardiovascular and back pain indications. The Corporate Governance Statement emphasizes the company's commitment to effective governance and ethical management.